NCT06160843View on ClinicalTrials.gov

Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2028

Conditions
Relapsed Peripheral T-Cell LymphomaRefractory Peripheral T-Cell Lymphoma
Interventions
DRUG

Pembrolizumab IV infusion Q3W, with daily oral Olaparib.

Pembrolizumab IV infusion 200 mg Q3W, with daily oral Olaparib 300mg BID, over a 3-week cycle.

Trial Locations (1)

168583

RECRUITING

National Cancer Centre, Singapore, Singapore

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

National Medical Research Council (NMRC), Singapore

OTHER_GOV

lead

National Cancer Centre, Singapore

OTHER